Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
Alamar Biosciences reported an 82% increase in total revenue for Q2 2026 to $29.4 million, driven by growth in instrument placements and consumable sales. The company launched new multiplexed blood-based immunoassays for neurodegenerative disease and immune profiling, expanded strategic partnerships, and provided full-year revenue guidance of $116–…